Scrip - Pharma News And Expert Analysis For Commercial Decision Makers since 1972

Scrip Asia 100 ebook

Citeline's latest Scrip Asia 100 e-book is live! Visit the microsite to download the report.


Spotlight On ASH


Focus On Asia


Data Analysis


R&D


Sweden’s Mendus Clears Regulatory Path For Vididencel Registration Trial

 
• By 

Following promising Phase II data presented at ASH on the company's allogenic leukemia-derived dendritic cell vaccine, Mendus has secured support from the FDA and the EMA for pivotal studies starting later this year.

Merck KGaA’s AI Platform Architect On Redefining The Drug Discovery Process

 

The head of AI and automation in drug discovery at Merck KGaA’s life science business talked to Scrip about the company’s AI-powered platform that leverages a “gold mine” of proprietary R&D data, better in silico predictions and the next frontier of AI.

New Year’s Hangover: Neumora’s Phase III Failure In Depression Surprises

 
• By 

Neumora, one of two firms testing kappa opioid receptor antagonism in depression, failed its first of three Phase III studies. The company’s share price crashed sharply.

Poolbeg Startles Investors With Plan To Hook Up With Hookipa

 
• By 

The new year is only a couple of days old but the Anglo-Irish biotech has agreed a sale to Hookipa that will create a US-listed entity around HB-700, which targets multiple KRAS mutations in lung, colorectal and pancreatic cancers, and Poolbeg's Phase II-ready drug which is designed to prevent cancer immunotherapy-induced cytokine release syndrome.

Business


Deal Watch: Regeneron Quietly Acquires UK Ophthalmology Firm Oxular

 

Plus deals involving Pfizer/Atavistik, Immedica/Marinus, J&J/Kaken, Ikena/Inmagene, Corxel/Vincentage, Rapt/Jemincare, Sanofi/Corxel, Bristol Myers Squibb/BioArctic, NGM/kdT Ventures and more.

2024 Drug Launches Reflect A Breakout Year For Liver Disease

 

The year’s new drugs included the first drug approved for non-alcoholic steatohepatitis (NASH) and two drugs for primary biliary cholangitis (PBC).

Sweden’s Mendus Clears Regulatory Path For Vididencel Registration Trial

 
• By 

Following promising Phase II data presented at ASH on the company's allogenic leukemia-derived dendritic cell vaccine, Mendus has secured support from the FDA and the EMA for pivotal studies starting later this year.

Merck KGaA’s AI Platform Architect On Redefining The Drug Discovery Process

 

The head of AI and automation in drug discovery at Merck KGaA’s life science business talked to Scrip about the company’s AI-powered platform that leverages a “gold mine” of proprietary R&D data, better in silico predictions and the next frontier of AI.

Scrip Originals


Deal Watch: Regeneron Quietly Acquires UK Ophthalmology Firm Oxular

 

Plus deals involving Pfizer/Atavistik, Immedica/Marinus, J&J/Kaken, Ikena/Inmagene, Corxel/Vincentage, Rapt/Jemincare, Sanofi/Corxel, Bristol Myers Squibb/BioArctic, NGM/kdT Ventures and more.

Finance Watch: As Cash Dwindles, Biotechs Cut Costs, Sell Assets, Merge, Assess Options

 
• By 

Restructuring Edition: Vincerx strategic review ends with a merger, Viracta halts last clinical trial and assesses options, and Achilles completed a strategic review by selling assets to AstraZeneca. Also, Synaptogenix explores opportunities, while GenSight warns its cash is running out.

Pipeline Watch: Thirteen Approvals And Eight Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Stock Watch: Pfizer And Novo Nordisk Deliver Christmas Gifts Both Welcome And Unwanted

 
• By 

While Pfizer’s analysts’ meeting cheered its investors with clear guidance, Novo Nordisk presented disappointing obesity data. The true value of CagriSema cannot be estimated without more information, however.